- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
[作者：Azim, HA; Michiels, S; Bedard, PL; Singhal, SK; Criscitiello, C; Ignatiadis, M; Haibe-Kains, B; Piccart, MJ; Sotiriou, C; Loi, S,期刊：Clinical Cancer Research, 页码：1341-1351 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according...
- Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
[作者：Donahue, TR; Tran, LM; Hill, R; Li, YF; Kovochich, A; Calvopina, JH; Patel, SG; Wu, NP; Hindoyan, A; Farrell, JJ; Li, XM; Dawson, DW; Wu, H,期刊：Clinical Cancer Research, 页码：1352-1363 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: To carry out an integrative profile of human pancreatic ductal adenocarcinoma (PDAC) to identify prognosis-significant genes and their related pathways. Experimental Design: A concordant survival-based whole gen...
- Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of beta(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression
[作者：Lange, T; Ullrich, S; Muller, I; Nentwich, MF; Stubke, K; Feldhaus, S; Knies, C; Hellwinkel, OJC; Vessella, RL; Abramjuk, C; Anders, M; Schroder-Schwarz, J; Schlomm, T; Huland, H; Sauter, G; Schumacher, U,期刊：Clinical Cancer Research, 页码：1364-1373 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: To establish xenograft mouse models of metastatic and nonmetastatic human prostate cancer and to apply these models to the search for aberrant glycosylation patterns associated with tumor progression in vivo and...
- High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
[作者：Yoshihara, K; Tsunoda, T; Shigemizu, D; Fujiwara, H; Hatae, M; Fujiwara, H; Masuzaki, H; Katabuchi, H; Kawakami, Y; Okamoto, A; Nogawa, T; Matsumura, N; Udagawa, Y; Saito, T; Itamochi, H; Takano, M; Miyagi, E; Sudo, T; Ushijima, K; Iwase, H; Seki, H; Terao, Y; Enomoto, T; Mikami, M; Akazawa, K; Tsuda, H; Moriya, T; Tajima, A; Inoue, I; Tanaka, K,期刊：Clinical Cancer Research, 页码：1374-1385 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: High-grade serous ovarian cancers are heterogeneous not only in terms of clinical outcome but also at the molecular level. Our aim was to establish a novel risk classification system based on a gene expression s...
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
[作者：Wilmott, JS; Long, GV; Howle, JR; Haydu, LE; Sharma, RN; Thompson, JF; Kefford, RF; Hersey, P; Scolyer, RA,期刊：Clinical Cancer Research, 页码：1386-1394 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: To evaluate the effects of treatment with the potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment. Experimenta...
- Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
[作者：Forero-Torres, A; de Vos, S; Pohlman, BL; Pashkevich, M; Cronier, DM; Dang, NH; Carpenter, SP; Allan, BW; Nelson, JG; Slapak, CA; Smith, MR; Link, BK; Wooldridge, JE; Ganjoo, KN,期刊：Clinical Cancer Research, 页码：1395-1403 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: AME-133v is a humanized monoclonal antibody engineered to have increased affinity to CD20 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) better than rituximab. Safety, pharmacokinetics, and eff...
- Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
[作者：Yoo, DS; Kirkpatrick, JP; Craciunescu, O; Broadwater, G; Peterson, BL; Carroll, MD; Clough, R; MacFall, JR; Hoang, J; Scher, RL; Esclamado, RM; Dunphy, FR; Ready, NE; Brizel, DM,期刊：Clinical Cancer Research, 页码：1404-1414 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: We assessed the safety and efficacy of synchronous VEGF and epidermal growth factor receptor (EGFR) blockade with concurrent chemoradiation (CRT) in locally advanced head and neck cancer (HNC). Experimental Desi...
- Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
[作者：Patterson, DM; Zweifel, M; Middleton, MR; Price, PM; Folkes, LK; Stratford, MRL; Ross, P; Halford, S; Peters, J; Balkissoon, J; Chaplin, DJ; Padhani, AR; Rustin, GJS,期刊：Clinical Cancer Research, 页码：1415-1425 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents. Experimental Design: Escalating doses of OXi4503 were given ...
- Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
[作者：Noonan, K; Rudraraju, L; Ferguson, A; Emerling, A; Pasetti, MF; Huff, CA; Borrello, I,期刊：Clinical Cancer Research, 页码：1426-1434 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: To show that the immunomodulatory drug lenalidomide can be used in patients with relapsed multiple myeloma to augment vaccine responses. Experimental Design: Early phase clinical trial of patients with multiple ...
- A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck
[作者：Lewis, CM; Glisson, BS; Feng, L; Wan, FN; Tang, XM; Wistuba, II; El-Naggar, AK; Rosenthal, DI; Chambers, MS; Lustig, RA; Weber, RS,期刊：Clinical Cancer Research, 页码：1435-1446 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: To determine the disease control rate and toxicity of treating patients with aggressive cutaneous squamous cell carcinoma (CSCC) with neoadjuvant gefitinib. Experimental Design: A prospective phase II clinical t...
- CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
[作者：Aoe, K; Amatya, VJ; Fujimoto, N; Ohnuma, K; Hosono, O; Hiraki, A; Fujii, M; Yamada, T; Dang, NH; Takeshima, Y; Inai, K; Kishimoto, T; Morimoto, C,期刊：Clinical Cancer Research, 页码：1447-1456 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: Malignant pleural mesothelioma (MPM) is an aggressive and therapy-resistant neoplasm arising from the pleural mesothelial cells, without established indicators to predict responsiveness to chemotherapy. Experime...
- Sunitinib Therapy for Melanoma Patients with KIT Mutations
[作者：Minor, DR; Kashani-Sabet, M; Garrido, M; O'Day, SJ; Hamid, O; Bastian, BC,期刊：Clinical Cancer Research, 页码：1457-1463 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: Recent studies have shown activating KIT mutations in melanoma originating from mucosa, acral, or cumulative sun-damaged skin sites. We aimed to assess the predictive role of KIT mutation, amplification, or over...
- Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer
[作者：Schwarz, JK; Payton, JE; Rashmi, R; Xiang, T; Jia, YH; Huettner, P; Rogers, BE; Yang, Q; Watson, M; Rader, JS; Grigsby, PW,期刊：Clinical Cancer Research, 页码：1464-1471 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: Cervical tumor response on posttherapy 2[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) is predictive of survival outcome. The purpose of this study was to use gene expression profiling to ...
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
[作者：Doebele, RC; Pilling, AB; Aisner, DL; Kutateladze, TG; Le, AT; Weickhardt, AJ; Kondo, KL; Linderman, DJ; Heasley, LE; Franklin, WA; Varella-Garcia, M; Camidge, DR,期刊：Clinical Cancer Research, 页码：1472-1482 , 文章类型： Article，,卷期：2012年18-5]
- Purpose: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not every patient responds and acquired drug res...
|